Akeso (09926): Results from the HARMONi-GI1 study of ivonescimab combined with chemotherapy versus durvalumab combined with chemotherapy in first-line treatment of advanced biliary tract cancer prominently published at 2026 ESMO

Zhitong Finance APP News, Akeso (09926) announced that HARMONi-GI1/AK112309 has been selected as a Late-Breaking Abstract (LBA) for an oral presentation at the 2026 ESMO Congress Presidential Session, to be presented by the principal investigator, Academician Zhou Jian, President of Zhongshan Hospital Affiliated to Fudan University.